Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back

Amir Avan, Paola Pacetti, Michele Reni, Michele Milella, Enrico Vasile, Andrea Mambrini, Vanja Vaccaro, Sara Caponi, Stefano Cereda, Godefridus J. Peters, Maurizio Cantore, Elisa Giovannetti

Research output: Contribution to journalArticlepeer-review


The use of platinated agents in combination chemotherapy regimens for advanced pancreatic cancer is controversial owing to the lack of an outstanding impact on the outcome and a substantial increase in hematologic and extra-hematologic toxicities. Pharmacogenetic studies to identify patients who could benefit most from such therapies are urgently needed. The Xeroderma-Pigmentosum group-D polymorphism at codon-751 (XPD-Lys751Gln) emerged as the most significant independent predictor for death- and progression-risk in our previous study on functional polymorphisms in 122 advanced pancreatic cancer patients treated with cisplatin-docetaxel-capecitabine-gemcitabine and cisplatin-epirubicin-capecitabine-gemcitabine (or EC-GemCap). To confirm the prognostic role of this variable, we further evaluated the correlation of XPD-Lys751Gln with outcome in another 125 patients treated with the same regimens, and 90 treated with gemcitabine monotherapy. Genotyping was successfully carried out in the vast majority of DNA samples. Genotype frequencies followed Hardy-Weinberg equilibrium, and XPD-Lys751Gln was associated with differential progression-free and overall-survival. Multivariate analysis confirmed its prognostic significance in platinum-based regimens. In particular, XPD-Gln751Gln was significantly associated with risk of death (hazard ratio, HR = 1.7, 95% confidence interval [CI], 1.1-2.6, p = 0.011) and risk of progression (HR = 1.7, 95% CI, 1.1-2.5, p = 0.013). No correlation was observed in gemcitabine monotherapy-treated patients. The analysis of DNA damage using extra-long-PCR in lymphocytes supported the association of XPD-Gln751Gln with greater resistance to cisplatin-induced damage. The increasing evidence of XPD-Lys751Gln impact on the outcome of gemcitabine-cisplatin-based polychemotherapy leads to plan prospective studies to validate the role of this polymorphism as a new tool for optimization of the currently available treatments in pancreatic cancer. What's new? Recent advances in treatments of pancreatic cancer include a novel combination therapy of cisplatin-gemcitabine- based polychemotherapeutic regimens. However, this treatment shows increased hematologic or extra-hematologic side effects calling for the identification of biomarkers that predict treatment outcome. In this study, the XPD-Lys751Gln gene polymorphism was identified as the most significant independent predictor for death and progression-risk in pancreatic cancer patients who underwent such treatment. Determined by a simple blood test, the polymorphism offers an innovative tool for optimizing palliative chemotherapy in advanced pancreatic cancers. The authors call for prospective trials to validate their findings, which may ultimately lead to a more individualized treatment in selected pancreatic cancer patients.

Original languageEnglish
Pages (from-to)1016-1022
Number of pages7
JournalInternational Journal of Cancer
Issue number4
Publication statusPublished - Aug 15 2013


  • clinical outcome
  • pancreatic cancer
  • polychemotherapy
  • prognostic factor
  • XPD-Lys751Gln polymorphism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back'. Together they form a unique fingerprint.

Cite this